Medically reviewed on January 10, 2018.
Applies to the following strengths: 10 mg; 25 mg; 50 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for HIV Infection
Therapy-naive or therapy-experienced integrase strand transfer inhibitor (INSTI)-naive patients or virologically-suppressed patients switching to this drug plus rilpivirine: 50 mg orally once a day
Therapy-naive or therapy-experienced INSTI-naive patients when coadministered with certain UGT1A or CYP450 3A inducers: 50 mg orally twice a day
INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg orally twice a day
-Rilpivirine dose is 25 mg orally once a day for patients switching to this drug plus rilpivirine.
-The manufacturer product information should be consulted for relevant UGT1A or CYP450 3A inducers.
-In INSTI-experienced patients, alternative combinations that do not include metabolic inducers should be considered where possible.
-In combination with other antiretroviral agents, for the treatment of HIV-1 infection
-In combination with rilpivirine, as a complete regimen for the treatment of HIV-1 infection to replace a stable antiretroviral regimen in patients who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to either drug
Usual Pediatric Dose for HIV Infection
30 to less than 40 kg: 35 mg orally once a day
At least 40 kg: 50 mg orally once a day
-Recommended for therapy-naive or therapy-experienced INSTI-naive patients
-If certain UGT1A or CYP450 3A inducers are coadministered, the weight-based dose should be increased to twice a day; the manufacturer product information should be consulted for relevant inducers.
-Safety and efficacy not established in INSTI-experienced patients with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).
Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection
Renal Dose Adjustments
Therapy-naive or therapy-experienced INSTI-naive patients:
-Mild, moderate, or severe renal dysfunction: No adjustment recommended.
INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance):
-Mild or moderate renal dysfunction: No adjustment recommended.
-Severe renal dysfunction: Caution recommended.
-INSTI-experienced patients with severe renal dysfunction: Reduced dolutegravir levels may lead to loss of therapeutic effect and development of resistance to this drug or other concomitant antiretroviral agents.
Liver Dose Adjustments
Mild to moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.
-Hypersensitivity to the active component or any of the ingredients
-Coadministration with dofetilide
Safety and efficacy have not been established in pediatric patients weighing less than 30 kg or who are INSTI-experienced.
Consult WARNINGS section for dosing related precautions.
Data not available
-May administer without regard to food
-Administer products containing polyvalent cations (e.g., aluminum or magnesium) and supplements containing calcium or iron (including multivitamins containing calcium or iron) 6 hours before or 2 hours after this drug; may administer calcium or iron supplements and this drug together with food
-Consult the manufacturer product information regarding missed doses.
-For 10 mg tablets: Store and dispense in original bottle and protect from moisture; keep bottle tightly closed and do not remove desiccant.
-Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
-Hepatic: For hepatotoxicity (during therapy), especially in patients with liver disease such as hepatitis B or C
-Read the US FDA-approved patient labeling (Patient Information).
-Contact healthcare provider at once if rash develops; stop this drug and other suspect agents immediately and seek medical attention if rash associated with any of the following symptoms develop: fever, general ill feeling, extreme tiredness, muscle/joint aches, blisters/peeling of skin, oral blisters/lesions, eye inflammation, facial swelling, swelling of eyes/lips/tongue/mouth, difficulty breathing, and/or signs/symptoms of liver problems (e.g., yellowing of skin/whites of eyes, dark/tea-colored urine, pale-colored stools/bowel movements, nausea, vomiting, loss of appetite, pain/aching/sensitivity on right side below ribs).
-Consult healthcare provider at once if any signs/symptoms of infection.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about dolutegravir
- Dolutegravir Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 13 Reviews
- Drug class: integrase strand transfer inhibitor
Other brands: Tivicay